{
  "name" : "dacemirror.sci-hub.se_journal-article_1eebdb372c295649dc8e38a2da401913_lazarovits2018.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Synthesis of Patient-Specific Nanomaterials",
    "authors" : [ "James Lazarovits", "Yih Yang Chen", "Fayi Song", "Wayne Ngo", "Anthony J. Tavares", "Yi-Nan Zhang", "Julie Audet", "Bo Tang", "Qiaochu Lin", "Mayra Cruz Tleugabulova", "Stefan Wilhelm", "Jonathan R. Krieger", "Thierry Mallevaey", "Warren C. W. Chan" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "KEYWORDS: Nanotechnology, personalized medicine, patient-specific nanomaterials, protein corona, protein nanoparticles, mass spectrometry\nNanomaterials are integral components in the diagnosticand therapeutic toolbox and possess a unique set of optical, magnetic, and electrical properties that are derived from their material composition.1 These parameters include the size, shape, and surface chemistry of the nanomaterial, all of which could dictate the biodistribution of the nanomaterial or its cellular interactions with the rest of the body.2−4 Since these nanomaterials are similar in size to biological molecules, manipulating these physicochemical properties can theoretically control their transport to specific organs and cells. The\ncore materials that have this high degree of synthetic tunability are built using substances that are exogenous to the body.1\nThese include metals, polymers, and different carbon allotropes. When these foreign materials are assembled into nanoparticles greater than 6 nm, they cannot be renally excreted and are not eliminated from the body.5 Therefore,\nReceived: August 23, 2018 Revised: November 30, 2018 Published: December 10, 2018\n© 2018 American Chemical Society 116 DOI: 10.1021/acs.nanolett.8b03434 Nano Lett. 2019, 19, 116−123\nN an\no L\net t.\n20 19\nD ow\nnl oa\nde d\nfr om\np ub\ns. ac\ns. or\ng by\nM ID\nW E\nST E\nR N\nexposure to these nanomaterials raises numerous concerns surrounding toxicity, inflammation, and activation of innate or adaptive immunity, especially following repeated administrations.6−11 In order to mitigate these side effects, several groups have used endogenous materials found within the body, such as lipids, to produce biocompatible nanoparticles.12,13 Since the body contains a reservoir of many different types of endogenous building block materials, we can use this supply to build libraries of nontoxic and nonimmunogenic personalized nanostructures. However, current methods cannot produce personalized nanostructures with the same degree of size and shape tunability as their exogenous counterparts.1 Here we demonstrate a solution to this problem with a simple threestep templating strategy to engineer personalized nanoparticles. These personalized nanoparticles have the same level of design freedom and complexity as exogenous nanomaterial classes while being nontoxic and nonimmunogenic. Proteins are an abundant class of endogenous materials that can be exploited as building blocks for nanoparticle synthesis. Protein adsorption to nanoparticle surfaces is seen as a major problem for nanomaterial design,14 because it obfuscates a nanoparticle’s underlying synthetic properties. Previous work has shown that the types and abundances of proteins that adsorb to nanoparticles are predictable and reproducible, because it depends on the underlying nanoparticle size, shape, and surface chemistry.14−19 However, we can neither prevent protein adsorption, nor has the field found a way to exploit it for a useful application. In this study, we discovered how to exploit protein adsorption on nanostructures to build personalized protein nanoparticles (PNP). To do this, we incubated nanoparticles with biological fluids that were isolated from animals and humans, cross-linked the surface-\nadsorbed proteins in place, and removed the internal nanoparticle core to leave a nanostructure composed entirely of endogenous and patient-derived proteins (Figure 1a). Since size, shape, and surface chemistry tunability depends on the nanoparticle core template, we used gold nanoparticles (AuNP) because they have the broadest size range of any nanomaterial (from 2 to 500 nm), can be constructed into many different shapes (rods, spheres etc.), and are readily surface-modified.20−22 We combined the synthetic tunability offered by AuNPs with the phenomenon of protein adsorption to create PNP that have the same level of size and shape tunability as AuNP. We began with AuNPs20,21 that were 50 nm in diameter and coated them with pooled human serum. We separated the protein-coated AuNPs from unbound serum proteins using a rigorous centrifugation and washing protocol.16 The surfaceadsorbed proteins were cross-linked into a rigid “shell” using a photochemically activated, heterobifunctional, sulfo-LC-SDA cross-linker.23 To make the PNP composed only of protein, we needed to remove the exogenous AuNP core. Cyanidecontaining etching solutions have been used in templating strategies that incorporate nucleic acids24 and polymers,25 but they are hazardous to work with and irreversibly denature proteins.26,27 Consequently, we chose an etching solution that contains potassium-iodide/iodine, because they do not form irreversible side chain adducts27,28 (Figure 1b). After purification, we used inductively coupled plasma mass spectrometry to measure the atomic gold content of our PNP, and confirmed that PNP were essentially metal-free with roughly 35 ppb gold content (Figure S1). We also quantified the loss of gold and protein over the reaction and determined we achieved a 78% yield (Figure S2). Transmission electron microscopy revealed that PNP were size and shape tunable\nDOI: 10.1021/acs.nanolett.8b03434 Nano Lett. 2019, 19, 116−123\n117\nbecause they remained spherical and consistently 15 nm larger than their AuNP templates. Their zeta potentials were always 7 mV less negative (Figure 1c,d, Figure S3, and Table S1). Overall, these results show a patient-derived nanostructure that is free of exogenous materials and approximates the template core size and morphology. We next sought to expand our control over size and shape tunability. We therefore synthesized 15 and 30 nm spherical AuNPs, and 30 nm × 10 nm rod-shaped AuNPs.29 We confirmed that PNPs were size and shape tunable, as spherical PNPs maintained the same 15 nm increase in diameter across all sizes (Figure 1, parts e, h, and k, and Table S1). On the basis of the unique geometry of the nanorod templates, we\nfound they increased by 7 nm along both the longitudinal and transverse dimensions (Figure 1, parts f, i, and l, and Table S1). All PNP structures were 5.0 to 13.5 mV less anionic than their respective AuNP templates (Figure 1, parts g, j, m). Thus, we used AuNPs to build size and shape tunable PNPs. Changing the composition of the adsorbed proteins influences biological fate.14 It is also known that changing nanoparticle surface chemistry changes the enrichment pattern of proteins on the surface. Therefore, since different applications may require different compositions, we next explored the flexibility of our synthetic method by changing both the enrichment patterns of proteins, and the sources of the protein building blocks. We functionalized the surface of\nDOI: 10.1021/acs.nanolett.8b03434 Nano Lett. 2019, 19, 116−123\n118\n50 nm AuNPs with neutral, anionic, or cationic ligands to modify the profile of adsorbed serum proteins species in order to yield compositionally distinct PNPs (Figure 2a).14 We produced five unique classes of PNPs with different surface chemistries (Figure 2b−d) (see Materials and Methods and Table S2), and the proteins were analyzed using high resolution liquid chromatography tandem mass spectrometry. Each PNP had compositionally distinct protein populations (Figure S4). We confirmed each profile was distinct using both principal component (PCA) and canonical centroid analysis (CCA) (Figure 2, parts e and f, and Figure S5). Moving beyond serum, we next explored whether we could build PNPs from other biological fluids. We successfully engineered PNP from tears, saliva, and breast milk (Figure 2a). Each PNP contained a diverse array of protein building blocks that differed from one another in a statistically significant manner (Figure 2g−l and Figure S6). Interestingly, PNP size, shape, and charge remained constant regardless of the incubated biological fluid (Table S2). Since these PNPs consist of crosslinked self-proteins, we next tested the immunogenicity and toxicity of PNPs in vitro and in vivo. Since PNPs built from serum contain complement proteins within their structure (Figure S4), we measured the dose-\ndependent relationship of serum-PNP on complement activation and hemolysis. We incubated 50 nm AuNP templates with isolated serum from inbred C57BL/6 mice to construct host-specific PNPs. We found that PNPs did not activate complement pathways nor induce hemolysis (Figure 3a). However, PNPs showed some hemolytic activity at a very high dose of 250 mg/kg (Figure 3b). We conjugated fluorescent dyes to the PNP (Figure S7) and used Förster resonance energy transfer (FRET)30 (Figure S8) to show they degrade when exposed to Proteinase K (Figure S9). We then exposed bone-marrow derived dendritic cells to PNPs and found that they did not exhibit any measurable activation (Figure S10).31,32\nAfter characterizing the safety and behavior of PNPs in vitro, we next performed both short-term and long-term studies in C57BL/6 mice in vivo. We first determined the short-term in vivo toxicity and immunogenicity by injecting C57BL/6 mice with 50 mg/kg of C57BL/6-PNPs. PNPs did not induce any liver toxicity (Figure S11) nor did they cause the production of chemokines and cytokines involved in early inflammation and immune responses (Figure S12). We next evaluated whether PNPs induced adaptive immunity following repeated administrations over a 28-day period. Mice were injected with 50\nDOI: 10.1021/acs.nanolett.8b03434 Nano Lett. 2019, 19, 116−123\n119\nmg/kg of PNP, PBS, free serum protein, or a positive control of lipopolysaccharide (LPS) at 2 mg/kg on days 0 and 14. Their weights were recorded every 3 days. Mice treated with LPS lost 20% of their body weight 3 days after both the first and second injections (Figure S13), whereas PBS, protein, and\nPNP did not. Histopathology analysis indicated severe inflammation and neutrophil infiltration following LPS treatment, but no inflammation in the PBS, protein and PNP groups (Figure S14). Splenocytes were counted to determine the degree of immune cell recruitment, and we found no\nDOI: 10.1021/acs.nanolett.8b03434 Nano Lett. 2019, 19, 116−123\n120\ndifference between PBS, protein, and PNP groups, but a 2-fold increased cell number was found in the LPS group (Figure 3C, ***P < 0.001). Similarly, free proteins and PNPs did not upregulate expression of major histocompatibility class II (MHCII), CD86 or the activation marker CD69 by B (B220+) cells (Figures 3d, S15, and S16).33 This lack of B cell expansion and activation suggested that anti-PNP antibodies were unlikely to be produced. We similarly showed that neither free protein nor PNPs increased IgG or IgM production compared to the control (Figure 3e,f). Our results demonstrate that we can synthesize PNPs in microgram to milligram quantities, which do not activate innate or adaptive immune responses in mice, and may therefore be safe for long-term use in vivo. In pursuit of future therapeutic and diagnostic applications, we next needed to engineer PNPs with greater complexity and functionality. We investigated whether we could exert direct control of the PNP composition, and incorporate biologically active macromolecules such as enzymes that can interact with the surrounding biological environment. We used horseradish peroxidase (HRP) as the model enzyme, since it generates a chromogenic signal that can be measured using spectrophotometry. In this synthetic process, HRP was initially mixed with serum, and this mixture was incubated with the AuNP template (Figure 4a). After synthesis and purification, we found that the enzymatic activity of the resulting HRP-PNP correlated linearly with the proportion of HRP initially spiked into the serum (r2 = 0.84). (Figure 4b). We next exposed the HRP-PNP to serum and found it both remained catalytically\nactive and resisted subsequent protein adsorption to the same degree as polyethylene glycol-conjugated AuNP (Figure S17). After confirming functional and structural stability, they were intravenously administered in vivo. HRP-PNP remained both catalytically active and were preferentially taken up by more cells compared to free HRP (Figure 4c, P < 0.0001). These results show these multicomponent PNP assemblies can be loaded with specific protein cargos that remain functionally intact even when delivered to cells inside of the body. We exploited the predictable nature of protein−nanoparticle interactions to assemble patient-derived macromolecules into nanomaterials with the same design freedom and complexity as AuNP. Protein corona formation is well studied, but predominately seen as a bane to nanomaterial design. We have demonstrated how to convert this phenomenon into a solution to make a truly unique class of patient-specific nanoparticles. Specifically, PNP synthesis is highly robust as they can be engineered from different proteins and into varying sizes and shapes. Consequently, our strategy is generalizable and readily amenable to modifications. Future studies should explore ways to increase the complexity of the template, the types of integrated cargo, and how these features influence therapeutic efficacy, immunogenicity, and toxicity. Looking forward, we envision the PNP synthetic process will be integrated into the therapeutic and diagnostic workflow when patients visit the clinic or hospital. When patients visit, their biological fluids will be isolated and used to create a personalized treatment strategy (Figure S18). As a first step to explore this, we took sera from human patients from a\nDOI: 10.1021/acs.nanolett.8b03434 Nano Lett. 2019, 19, 116−123\n121\ndiverse range of ethnicity, age and gender, and synthesized their PNPs (Figure 5a,b). Each patient produced PNPs with distinct compositions (Figure 5c). Using PCA and CCA, we validated that this process was truly patient-specific. Each PNP contained a molecular fingerprint that could be used to discriminate each patient from the rest of the sample cohort (Figure 5d,e). In the future, we envision that biological fluids will be isolated from patients, the PNPs designed with therapeutics and diagnostic agents, and then readministered into the patient for medical use (Figure 6). In addition, the protein biomarkers could be used to archive a patient’s biological profile at the time of collection, monitor disease progression, or response to therapy.34,35 This can be achieved because the personalized PNP contained a chemical signature that was unique to the patient. Interestingly, 100 of the proteins enriched from these biological fluids are known FDA clinical biomarkers (Table S3).36 Overall, we have provided a generalized strategy to build patient-specific nanomaterials that can be used in therapeutic and diagnostic applications that will become integral components in the toolbox for personalized medicine.\n■ ASSOCIATED CONTENT *S Supporting Information The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.nanolett.8b03434.\nFigures S1−19, Tables S1 and S2, and the materials and methods PDF)\nRaw and processed proteomics analysis data (XLSX)\n■ AUTHOR INFORMATION Corresponding Author *(W.C.W.C) E-mail: warren.chan@utoronto.ca."
    }, {
      "heading" : "ORCID",
      "text" : "Warren C. W. Chan: 0000-0001-5435-4785"
    }, {
      "heading" : "Author Contributions",
      "text" : "J.L. and W.C.W.C. conceived the idea and wrote the manuscript. J.L., Y.Y.C., W.N., Y.-N.Z, J.A., M.C.T., J.R.K., T.M. and W.C.W.C. analyzed the data. J.L. conducted the experiments with support from Y.Y.C, W.N., Y.-N.Z, B.T., M.C.T., Q.L., F.S., A.J.T., S.W. and J.R.K. All authors read and commented on the manuscript."
    }, {
      "heading" : "Notes",
      "text" : "The authors declare no competing financial interest. Data Availability Statement: Authors can confirm that all relevant data are included in the paper and/or its Supporting Information files.\n■ ACKNOWLEDGMENTS The authors would like to thank C. Walkey, D. Holmyard, S. Chryssoulis, S. Sindhwani, S. Zhou, W. Poon, and B. Ouyang for their support and advice. The authors would also like to thank the Natural Sciences and Engineering Research Council (NSERC) and Canadian Institute of Health Research (CIHR) for funding support. J.L., Y.Y.C., W.N., Y.Z. thanks NSERC for graduate student fellowship. J.L. acknowledges Ontario Graduate Scholarship. A.J.T. acknowledges CIHR for post-doctoral fellowship.\n■ REFERENCES (1) Nel, A. E.; Mad̈ler, L.; Velegol, D.; Xia, T.; Hoek, E. M. V.; Somasundaran, P.; Klaessig, F.; Castranova, V.; Thompson, M. Nat. Mater. 2009, 8 (7), 543−557. (2) Tenzer, S.; Docter, D.; Rosfa, S.; Wlodarski, A.; Rekik, A.; Knauer, S. K.; Bantz, C.; Nawroth, T.; Bier, C.; Sirirattanapan, J.; et al. ACS Nano 2011, 5 (9), 7155−7167. (3) Hong, M.; Zhu, S.; Jiang, Y.; Tang, G.; Pei, Y. J. Controlled Release 2009, 133 (2), 96−102. (4) Dai, Q.; Wilhelm, S.; Ding, D.; Syed, A. M.; Sindhwani, S.; Zhang, Y.; Chen, Y. Y.; Macmillan, P.; Chan, W. C. W. ACS Nano 2018, 12, 8423−8435. (5) Soo Choi, H.; Liu, W.; Misra, P.; Tanaka, E.; Zimmer, J. P.; Itty Ipe, B.; Bawendi, M. G.; Frangioni, J. V. Nat. Biotechnol. 2007, 25 (10), 1165−1170. (6) Aillon, K. L.; Xie, Y.; El-Gendy, N.; Berkland, C. J.; Forrest, M. L. Adv. Drug Delivery Rev. 2009, 61 (6), 457−466. (7) Sayes, C. M.; Marchione, A. A.; Reed, K. L.; Warheit, D. B. Nano Lett. 2007, 7 (8), 2399−2406. (8) Alkilany, A. M.; Murphy, C. J. J. Nanopart. Res. 2010, 12 (7), 2313−2333. (9) Dobrovolskaia, M. A.; Germolec, D. R.; Weaver, J. L. Nat. Nanotechnol. 2009, 4 (7), 411−414. (10) Cho, W. S.; Cho, M.; Jeong, J.; Choi, M.; Cho, H. Y.; Han, B. S.; Kim, S. H.; Kim, H. O.; Lim, Y. T.; Chung, B. H.; et al. Toxicol. Appl. Pharmacol. 2009, 236 (1), 16−24. (11) Chen, Y. S.; Hung, Y. C.; Liau, I.; Huang, G. S. Nanoscale Res. Lett. 2009, 4 (8), 858−864. (12) Langer, K.; Balthasar, S.; Vogel, V.; Dinauer, N.; Von Briesen, H.; Schubert, D. Int. J. Pharm. 2003, 257 (1−2), 169−180. (13) Kooijmans, S. A. A.; Vader, P.; van Dommelen, S. M.; van Solinge, W. W.; Schiffelers, R. M. Int. J. Nanomed. 2012, 7, 1525− 1541. (14) Walkey, C. D.; Chan, W. C. W. Chem. Soc. Rev. 2012, 41 (7), 2780−2799. (15) Walkey, C. D.; Olsen, J. B.; Guo, H.; Emili, A.; Chan, W. C. W. J. Am. Chem. Soc. 2012, 134 (4), 2139−2147. (16) Walkey, C.; Olsen, J.; Song, F.; Liu, R.; Guo, H.; Olsen, W.; Cohen, Y.; Emili, A.; Chan, W. C. W. ACS Nano 2014, 8 (3), 2439− 2455. (17) Lundqvist, M.; Stigler, J.; Elia, G.; Lynch, I.; Cedervall, T.; Dawson, K. A. Proc. Natl. Acad. Sci. U. S. A. 2008, 105 (38), 14265− 14270. (18) Cedervall, T.; Lynch, I.; Lindman, S.; Berggård, T.; Thulin, E.; Nilsson, H.; Dawson, K. A.; Linse, S. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (7), 2050−2055. (19) Monopoli, M. P.; Walczyk, D.; Campbell, A.; Elia, G.; Lynch, I.; Baldelli Bombelli, F.; Dawson, K. A. J. Am. Chem. Soc. 2011, 133 (8), 2525−2534. (20) Frens, G. Nature, Phys. Sci. 1973, 241, 20−22. (21) Perrault, S. D.; Chan, W. C. W. J. Am. Chem. Soc. 2009, 131 (47), 17042−17043. (22) Yeh, Y. C.; Creran, B.; Rotello, V. M. Nanoscale 2012, 4 (6), 1871−1880. (23) Gomes, A. F.; Gozzo, F. C. J. Mass Spectrom. 2010, 45 (8), 892−899. (24) Auyeung, E.; Cutler, J. I.; Macfarlane, R. J.; Jones, M. R.; Wu, J.; Liu, G.; Zhang, K.; Osberg, K. D.; Mirkin, C. A. Nat. Nanotechnol. 2012, 7 (1), 24−28. (25) Zhang, K.; Cutler, J. I.; Zhang, J.; Zheng, D.; Auyeung, E.; Mirkin, C. A. J. Am. Chem. Soc. 2010, 132 (43), 15151−15153. (26) Wood, M. A.; Riehle, M.; Wilkinson, C. D. W. Nanotechnology 2002, 13 (5), 605−609. (27) Fasco, M. J.; Stack, R. F.; Lu, S.; Hauer, C. R.; Schneider, E.; Dailey, M.; Aldous, K. M. Chem. Res. Toxicol. 2011, 24 (4), 505−514. (28) Ramachandran, L. Chem. Rev. 1956, 56 (2), 199−218. (29) Smith, D. K.; Korgel, B. A. Langmuir 2008, 24, 644−649.\nDOI: 10.1021/acs.nanolett.8b03434 Nano Lett. 2019, 19, 116−123\n122\n(30) Yun, C. S.; Javier, A.; Jennings, T.; Fisher, M.; Hira, S.; Peterson, S.; Hopkins, B.; Reich, N. O.; Strouse, G. F. J. Am. Chem. Soc. 2005, 127 (9), 3115−3119. (31) Niikura, K.; Matsunaga, T.; Suzuki, T. ACS Nano 2013, 7, 3926−3938. (32) Tarcha, P. J.; Chu, V. P.; Whittern, D. Anal. Biochem. 1987, 165 (1), 230−233. (33) Honda, S. I.; Sato, K.; Totsuka, N.; Fujiyama, S.; Fujimoto, M.; Miyake, K.; Nakahashi-Oda, C.; Tahara-Hanaoka, S.; Shibuya, K.; Shibuya, A. Nat. Commun. 2016, 7, 11498. (34) Hajipour, M. J.; Laurent, S.; Aghaie, A.; Rezaee, F.; Mahmoudi, M. Biomater. Sci. 2014, 2 (9), 1210−1221. (35) Hadjidemetriou, M.; Al-ahmady, Z.; Buggio, M.; Swift, J.; Kostarelos, K. Biomaterials 2019, 188, 118−129. (36) U.S. F.&D. Clinical Laboratory Improvement Amendments.\nDOI: 10.1021/acs.nanolett.8b03434 Nano Lett. 2019, 19, 116−123\n123"
    } ],
    "references" : [ ],
    "referenceMentions" : [ ],
    "year" : 2019,
    "abstractText" : "Nanoparticles are engineered from materials such as metals, polymers, and different carbon allotropes that do not exist within the body. Exposure to these exogenous compounds raises concerns surrounding toxicity, inflammation, and immune activation. These responses could potentially be mitigated by synthesizing nanoparticles directly from molecules derived from the host. However, efforts to assemble patient-derived macromolecules into structures with the same degree of size and shape tunability as their exogenous counterparts remains a significant challenge. Here we solve this problem by creating a new class of sizeand shape-tunable personalized protein nanoparticles (PNP) made entirely from patient-derived proteins. PNPs are built into different sizes and shapes with the same degree of tunability as gold nanoparticles. They are biodegradable and do not activate innate or adaptive immunity following single and repeated administrations in vivo. PNPs can be further modified with specific protein cargos that remain catalytically active even after intracellular delivery in vivo. Finally, we demonstrate that PNPs created from different human patients have unique molecular fingerprints encoded directly into the structure of the nanoparticle. This new class of personalized nanomaterial has the potential to revolutionize how we treat patients and can become an integral component in the diagnostic and therapeutic toolbox.",
    "creator" : "PTC Arbortext Advanced Print Publisher 11.1.4300/W Library-x64"
  }
}